UA103179C2 - Фармацевтическая композиция, которая содержит эзетимиб - Google Patents

Фармацевтическая композиция, которая содержит эзетимиб

Info

Publication number
UA103179C2
UA103179C2 UAA201007034A UAA201007034A UA103179C2 UA 103179 C2 UA103179 C2 UA 103179C2 UA A201007034 A UAA201007034 A UA A201007034A UA A201007034 A UAA201007034 A UA A201007034A UA 103179 C2 UA103179 C2 UA 103179C2
Authority
UA
Ukraine
Prior art keywords
ezetimibe
pharmaceutical composition
relates
formulations
disintegrant
Prior art date
Application number
UAA201007034A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ганеш Гат
Рао Пасупулети Гиридхара
Джавед Хуссейн
Original Assignee
Ратиофарм Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40416944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA103179(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ратиофарм Гмбх filed Critical Ратиофарм Гмбх
Publication of UA103179C2 publication Critical patent/UA103179C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается фармацевтической композиции, которая содержит эзетимиб в количестве от 5 до 20 масс.%, разжижитель в количестве от 50 до 85 масс.%, разрыхлитель в количестве от 3 до 25 масс.%, гидротропный солюбилизатор в количестве от 2 до 5 масс.%, связующее в количестве от 1 до 10 масс.% и вещество, которое смазывает, в количестве от 0,5 до 1 масс.% , причем эзетимиб имеет гранулометрический состав со значением d(0,9) в пределах от 7 до 20 мкм и значением d(0,5) в пределах от 4 до 10 мкм.
UAA201007034A 2007-12-10 2008-12-09 Фармацевтическая композиция, которая содержит эзетимиб UA103179C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2579DE2007 2007-12-10
PCT/EP2008/010431 WO2009074286A2 (en) 2007-12-10 2008-12-09 Pharmaceutical formulation comprising ezetimibe

Publications (1)

Publication Number Publication Date
UA103179C2 true UA103179C2 (ru) 2013-09-25

Family

ID=40416944

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007034A UA103179C2 (ru) 2007-12-10 2008-12-09 Фармацевтическая композиция, которая содержит эзетимиб

Country Status (7)

Country Link
US (1) US8858994B2 (ru)
EP (2) EP2217214B1 (ru)
CA (1) CA2708159C (ru)
EA (1) EA022269B1 (ru)
ES (1) ES2639995T3 (ru)
UA (1) UA103179C2 (ru)
WO (1) WO2009074286A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1252803B2 (en) 1999-12-01 2015-09-02 The Trustees Of Princeton University Complexes of form l2mx as phosphorescent dopants for organic leds
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
HUP1000327A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Composition containing nanostructured ezetibime and process for it's preparation
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
CN104173307A (zh) * 2014-08-29 2014-12-03 四川制药制剂有限公司 依折麦布片剂的制备方法
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
WO2019101150A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布片剂及其制备方法
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
WO2024042061A1 (en) * 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2024041746A1 (en) * 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9606319A (es) 1994-06-20 1997-05-31 Schering Corp Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
DE60216890T2 (de) 2001-01-26 2007-08-30 Schering Corp. Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1817280A1 (en) 2004-12-03 2007-08-15 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070049748A1 (en) 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008032338A2 (en) 2006-09-11 2008-03-20 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
CN101641146B (zh) 2007-01-20 2013-03-27 戴斯分析公司 通过膜的多相选择性物质传递
WO2008089984A2 (en) 2007-01-24 2008-07-31 Krka Process for the preparation of ezetimibe and derivatives thereof
EP2120882A2 (en) 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
CN101938995A (zh) 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液

Also Published As

Publication number Publication date
US8858994B2 (en) 2014-10-14
CA2708159A1 (en) 2009-06-18
EA201000752A1 (ru) 2010-12-30
ES2639995T3 (es) 2017-10-31
WO2009074286A3 (en) 2009-07-30
EP2217214B1 (en) 2017-07-19
EP2217214A2 (en) 2010-08-18
EA022269B1 (ru) 2015-12-30
EP2965752A1 (en) 2016-01-13
US20100291207A1 (en) 2010-11-18
WO2009074286A2 (en) 2009-06-18
CA2708159C (en) 2016-01-26

Similar Documents

Publication Publication Date Title
UA103179C2 (ru) Фармацевтическая композиция, которая содержит эзетимиб
MX2007004294A (es) Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion.
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
TW200637616A (en) Direct compression formulation and process
NZ600640A (en) Abuse-resistant formulations
PL1842534T3 (pl) Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
MX347753B (es) Formulaciones resistentes al abuso.
MX2007013084A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion.
WO2010149169A3 (en) Controlled release formulations
MX2011001782A (es) Composicion farmaceutica y su administracion.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
MX343358B (es) Tabletas de acetato de ulipristal.
TW200745003A (en) Novel compounds
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
PT1810676E (pt) Formulações de levetiracetam e métodos para a sua preparação
MY148844A (en) Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
IL190915A0 (en) Dry formulations of aripiprazole
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
WO2009039157A3 (en) Orlistat pharmaceutical formulations
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
MY144613A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same